share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  06/27 16:44
Moomoo AI 已提取核心訊息
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended Current Report on Form 8-K/A with the U.S. Securities and Exchange Commission on June 27, 2024. The report provides updates on the financial impact of the previously announced Spin-Off of certain business activities. Illumina has concluded its impairment testing and estimates a goodwill impairment charge of $1,466 million for the second quarter of 2024, which represents the full remaining carrying value of goodwill related to its GRAIL business as of March 31, 2024. Additionally, the company anticipates a $420 million impairment charge for the in-process research and development (IPR&D) intangible asset of GRAIL. These charges are not expected to result in any significant future cash expenditures and will be excluded from Illumina's non-GAAP financial metrics.
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended Current Report on Form 8-K/A with the U.S. Securities and Exchange Commission on June 27, 2024. The report provides updates on the financial impact of the previously announced Spin-Off of certain business activities. Illumina has concluded its impairment testing and estimates a goodwill impairment charge of $1,466 million for the second quarter of 2024, which represents the full remaining carrying value of goodwill related to its GRAIL business as of March 31, 2024. Additionally, the company anticipates a $420 million impairment charge for the in-process research and development (IPR&D) intangible asset of GRAIL. These charges are not expected to result in any significant future cash expenditures and will be excluded from Illumina's non-GAAP financial metrics.
總部位於加利福尼亞州聖迭戈的生物技術公司illumina,於2024年6月27日向美國證券交易委員會提交了一份修改後的8-K/A表格。報告提供了關於先前宣佈的特定業務活動分拆的財務影響的更新。illumina已經完成了減值測試,並估計爲2024年第二季度計提了1,466億美元的商譽減值費用,這代表了與其GRAIL業務相關的商譽的全部剩餘賬面價值,截至2024年3月31日。此外,公司預計在GRAIL的在研研發(IPR&D)無形資產上計提4.2億美元的減值損失。這些費用預計不會導致任何重大的未來現金支出,並將從illumina的非GAAP財務指標中排除。
總部位於加利福尼亞州聖迭戈的生物技術公司illumina,於2024年6月27日向美國證券交易委員會提交了一份修改後的8-K/A表格。報告提供了關於先前宣佈的特定業務活動分拆的財務影響的更新。illumina已經完成了減值測試,並估計爲2024年第二季度計提了1,466億美元的商譽減值費用,這代表了與其GRAIL業務相關的商譽的全部剩餘賬面價值,截至2024年3月31日。此外,公司預計在GRAIL的在研研發(IPR&D)無形資產上計提4.2億美元的減值損失。這些費用預計不會導致任何重大的未來現金支出,並將從illumina的非GAAP財務指標中排除。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息